Clinuvel Pharmaceuticals Stock Quote CUV - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

13.69

Bid

13.64

Ask

13.71

Volume

54,819

13.42 Day's Range 13.76

12.96 52 Week Range 18.20

Market Cap

685.921M

Previous Close

13.54

Open

13.53

Last Trade

13.7

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

87,042

Shares Outstanding

50,103,765

Dividend Yield

PE Ratio

19.25

Earnings Per Share (EPS)

0.71

Revenue

88.74M

Net Profit

35.64M

Sector

Medicinal Chems,botanicl Pds

Industry

Drugs-health R&d/testing Labs

Website

www.clinuvel.com

Headquarters

Melbourne, Victoria, Aus

Founded

2000

Clinuvel Pharmaceuticals Limited is listed in the Medicinal Chems,botanicl Pds sector of the Australian Stock Exchange with ticker CUV. The last closing price for Clinuvel Pharmaceuticals was AUD13.54. Over the last year, Clinuvel Pharmaceuticals shares have traded in a share price range of AUD 12.96 to AUD 18.20.

Clinuvel Pharmaceuticals currently has 50,103,765 shares outstanding. The market capitalization of Clinuvel Pharmaceuticals is AUD678.40 million. Clinuvel Pharmaceuticals has a price to earnings ratio (PE ratio) of 19.25.

FeaturedDBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes

FeaturedSMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service

FeaturedSBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance

Europe Approves Novel Australian Drug Developed for Rare Sun Disease

The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory approval from the European Medicines Agency (EMA...

Clinical Significance and Benefit from SCENESSE(R) in US Phase III EPP study

Clinical Significance and Benefit from SCENESSE(R) in US Phase III EPP study Primary endpoint shows a strong statistical trend in pain-free exposure following the treatment of the 'orphan...

Clinuvel Files European Marketing Authorisation Application for SCENESSE® (afamelanotide)

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has submitted a marketing authorisation application (MAA) for its first-in-class...

Clinuvel announces positive results of first Phase II US study of SCENESSE® in orphan disease erythropoietic protoporphyria ...

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY), a global biopharmaceutical company with unique expertise on the interaction of light and human skin...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.66	-4.59930313589	14.35	14.6	13.42	82264	13.8381747	DE
4	-0.31	-2.21428571429	14	14.86	13.42	76038	14.07919791	DE
12	-0.51	-3.59154929577	14.2	15.99	13.13	87042	14.41000915	DE
26	-1.31	-8.73333333333	15	17.71	13.13	80812	14.78871277	DE
52	-2.13	-13.4639696587	15.82	18.2	12.96	92424	15.07138321	DE
156	-21.3	-60.8745355816	34.99	36.628	12.96	101355	18.52735064	DE
260	-16.41	-54.5182724252	30.1	44.67	12.92	124973	22.09244829	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NHEONoble Helium Ltd	AUD 0.004 (100.00%)	250k
MHCManhattan Corporation Limited	AUD 0.002 (100.00%)	609.82k
MNCMerino and Co Ltd	AUD 1.07 (57.35%)	845.65k
VPRVolt Group Ltd	AUD 0.0015 (50.00%)	2.92M
ADDAdavale Resources Limited	AUD 0.003 (50.00%)	6.01M
AZLOArizona Lithium Ltd	AUD 0.001 (-66.67%)	467.47k
SLZOSultan Resources Ltd	AUD 0.001 (-50.00%)	164.29k
AKGAcademies Australasia Group Ltd	AUD 0.105 (-38.24%)	3.55k
NCCONAOS Emerging Opportunities Company Limited	AUD 0.005 (-37.50%)	95.74k
RNERenu Energy Limited	AUD 0.001 (-33.33%)	522.88k
OVTOvanti Ltd	AUD 0.0325 (30.00%)	86.85M
PNRPantoro Limited	AUD 0.11 (4.76%)	50.83M
BRNBrainchip Holdings Ltd	AUD 0.28 (10.89%)	39.21M
MMIMetro Mining Ltd	AUD 0.051 (4.08%)	37.23M
RDNRaiden Resources Limited	AUD 0.03 (-3.23%)	33.83M